87 related articles for article (PubMed ID: 7949248)
1. Oligonucleotides protect cells from the cytotoxicity of several anti-cancer chemotherapeutic drugs.
Blagosklonny MV; Neckers LM
Anticancer Drugs; 1994 Aug; 5(4):437-42. PubMed ID: 7949248
[TBL] [Abstract][Full Text] [Related]
2. An oligomer complementary to the 5' end region of MDR1 gene decreases resistance to doxorubicin of human adenocarcinoma-resistant cells.
Corrias MV; Tonini GP
Anticancer Res; 1992; 12(5):1431-8. PubMed ID: 1444203
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides.
Cucco C; Calabretta B
Cancer Res; 1996 Oct; 56(19):4332-7. PubMed ID: 8813118
[TBL] [Abstract][Full Text] [Related]
4. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo.
Hu Y; Cherton-Horvat G; Dragowska V; Baird S; Korneluk RG; Durkin JP; Mayer LD; LaCasse EC
Clin Cancer Res; 2003 Jul; 9(7):2826-36. PubMed ID: 12855663
[TBL] [Abstract][Full Text] [Related]
6. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis.
Uslu R; Borsellino N; Frost P; Gárban H; Ng CP; Mizutani Y; Belldegrun A; Bonavida B
Clin Cancer Res; 1997 Jun; 3(6):963-72. PubMed ID: 9815772
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
8. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice.
Citro G; D'Agnano I; Leonetti C; Perini R; Bucci B; Zon G; Calabretta B; Zupi G
Cancer Res; 1998 Jan; 58(2):283-9. PubMed ID: 9443406
[TBL] [Abstract][Full Text] [Related]
9. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light.
Ohga T; Koike K; Ono M; Makino Y; Itagaki Y; Tanimoto M; Kuwano M; Kohno K
Cancer Res; 1996 Sep; 56(18):4224-8. PubMed ID: 8797596
[TBL] [Abstract][Full Text] [Related]
10. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
Ramachandran C; Wellham LL
Anticancer Res; 2003; 23(3B):2681-90. PubMed ID: 12894558
[TBL] [Abstract][Full Text] [Related]
11. An antisense oligonucleotide carrier based on amino silica nanoparticles for antisense inhibition of cancer cells.
Peng J; He X; Wang K; Tan W; Li H; Xing X; Wang Y
Nanomedicine; 2006 Jun; 2(2):113-20. PubMed ID: 17292123
[TBL] [Abstract][Full Text] [Related]
12. Control of intracellular delivery of oligonucleotides by signal peptides and genetic expression in human cells.
Kubo T; Kanno K; Ohba H; Rumiana B; Fujii M
Nucleic Acids Symp Ser (Oxf); 2004; (48):303-4. PubMed ID: 17150599
[TBL] [Abstract][Full Text] [Related]
13. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
Miyake H; Chi KN; Gleave ME
Clin Cancer Res; 2000 May; 6(5):1655-63. PubMed ID: 10815883
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides.
Schaaf A; Sagi S; Langbein S; Trojan L; Alken P; Michel MS
Urol Oncol; 2004; 22(3):188-92. PubMed ID: 15271313
[TBL] [Abstract][Full Text] [Related]
15. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents.
Tishler RB; Calderwood SK; Coleman CN; Price BD
Cancer Res; 1993 May; 53(10 Suppl):2212-6. PubMed ID: 8485705
[TBL] [Abstract][Full Text] [Related]
16. 1,25-Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death.
Wang Q; Yang W; Uytingco MS; Christakos S; Wieder R
Cancer Res; 2000 Apr; 60(7):2040-8. PubMed ID: 10766196
[TBL] [Abstract][Full Text] [Related]
17. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
18. The inhibition of angiogenesis by antisense oligonucleotides to clusterin.
Jackson JK; Gleave ME; Gleave J; Burt HM
Angiogenesis; 2005; 8(3):229-38. PubMed ID: 16308731
[TBL] [Abstract][Full Text] [Related]
19. [Significance of formation of micronuclei in SCC VII murine cells treated with various chemotherapeutic agents].
Jeremić B; Sibamoto J; Abe M
Srp Arh Celok Lek; 1996; 124(7-8):169-74. PubMed ID: 9102841
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer.
Rait AS; Pirollo KF; Rait V; Krygier JE; Xiang L; Chang EH
Cancer Gene Ther; 2001 Oct; 8(10):728-39. PubMed ID: 11687896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
